BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for pozelimab as a treatment for adults and children as young as 1 year of age with CHAPLE disease (also known as CD55 deficiency with Hyperactivation of complement, Angiopathic thrombosis and Protein Losing Enteropathy or CD55-deficient protein-losing enteropathy).

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, February 28, 2023, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022, and to provide a business update.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, March 3, 2023 , at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2022.

Mirion Technologies, Inc. today announced that it has agreed to sell $150 million of shares of Class A common stock to certain funds and accounts advised by T. Rowe Price Investment Management, Inc. (“T. Rowe Price”), a global investment management organization.

Verrica Pharmaceuticals Inc. today announced the pricing of its underwritten offering of 750,000 shares of its common stock and pre-funded warrants to purchase 4,064,814 shares of common stock.

Orasis Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%).

Sensei Biotherapeutics, Inc. presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the late-breaker presentation of a patient case study from the Phase 3 Part A clinical trial of nomacopan in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

89bio, Inc. (Nasdaq: ETNB) today announced additional pegozafermin data from the Phase 2 ENTRIGUE study in severe hypertriglyceridemia (SHTG) will be presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology to be held March 4-6, 2023 in New Orleans.

IntelGenx Corp., a leader in pharmaceutical films, announced that the United States Patent and Trademark Office has granted a Notice of Allowance for U.S. Patent Application 16/053,383, entitled “Loxapine Film Oral Dosage Form.”.